Acute Myocardial Infarction
Conditions
Keywords
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Brief summary
Statins are usually used in AMI patients due to its strong anti-lipidemic effect, pleiotropic effect and tolerable safety profiles. Generally AMI patients are prescribed many drugs concomitantly; there are some risks due to the drug interaction. Especially, statins are reported to have many drug interactions, these might influence to therapeutic prognosis and safety in AMI patients. This study is conducted to administer the non-CYP3A4 metabolized statin, pitavastatin to AMI patients over 1 year, and the results will be compared with the other results from the KAMIR study which is expected to the large scale of AMI patients using statins be enrolled. Finally, from that comparison, we will investigate the influence of the statins metabolism by CYP3A4 to the therapeutic prognosis like death, major adverse cardiac events(MACE), and major ADR of statins like CK increase, myalgia.
Interventions
None listed
Sponsors
JW Pharmaceutical
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The patients who have taken pitavastatin since AMI
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death/MACE for 1 year after the registration | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Achievement of LDL cholesterol target level according to the NCEP ATP III guideline | 1 year |
| Abnormal change of lab value including CK etc | 1 year |
| Adverse event including myalgia | 1 year |
Countries
South Korea
Outcome results
None listed